Since cancer immunotherapy with immune checkpoint inhibitors of PD/PDL-1 and CTLA-4 limited efficacy to the patients due to resistance during the current decade, novel target is required for customized treatment due to tumor heterogeneity. V-domain Ig-containing suppressor of T cell activation (VISTA), a programmed death protein-1(PD-1) homolog expressed on T cells and on antigen presenting cells(APC), has emerged as a new target in several cancers. Though VISTA inhibitors including CA-170 are considered attractive in cancer immunotherapy to date, the information on VISTA as a potent biomarker of cancer prognosis and its combination therapy is still lacking to date. Thus, in this review, we discussed extracellular domain, ligands, expression, immune functions and clinical implications of VISTA and finally suggested conclusion and perspectives.

由于在当前十年中，PD/PDL-1 和 CTLA-4 免疫检查点抑制剂的癌症免疫疗法由于耐药性而对患者的疗效有限，因此由于肿瘤异质性，定制治疗需要新的靶点。含有 V 结构域 Ig 的 T 细胞活化抑制因子 (VISTA) 是一种在 T 细胞和抗原呈递细胞 (APC) 上表达的程序性死亡蛋白 1 (PD-1) 同系物，已成为多种癌症的新靶点。尽管迄今为止，包括 CA-170 在内的 VISTA 抑制剂被认为在癌症免疫治疗中具有吸引力，但迄今为止仍然缺乏关于 VISTA 作为癌症预后及其联合治疗的有效生物标志物的信息。因此，在这篇综述中，我们讨论了 VISTA 的细胞外结构域、配体、表达、免疫功能和临床意义，并最终提出了结论和观点。